Cell and gene therapy

#Cell and gene therapy #Cell therapy #Gene therapy #Webinar

Upcoming advances and challenges in cell & gene therapies webinar

Hosted by Drug Discovery World and supported by Bio-Techne this webinar will explore the advances and challenges taking place within the cell and gene therapy field. You will hear from Hans Schambye CEO at BOOST Pharma, Lucas Arruda, CSO at CuraCell, and Brandon Cieniewicz, Director, Research & Development at CERo… Read More

#News

#Cell and gene therapy #Cell therapy #Drug discovery #Webinar

Webinar: Advances and challenges in cell & gene therapies

Hosted by Drug Discovery World and supported by Bio-Techne this webinar will explore the advances and challenges taking place within the cell and gene therapy field. You will hear from Hans Schambye CEO at BOOST Pharma, Lucas Arruda, CSO at CuraCell, and Brandon Cieniewicz, Director, Research & Development at CERo… Read More

#News

#Cell and gene therapy #Cell therapy #Drug discovery #Gene therapy #Webinar

Have you registered for our CGT webinar?

Hosted by Drug Discovery World and supported by Bio-Techne this webinar will explore the advances and challenges taking place within the cell and gene therapy field. You will hear from Hans Schambye CEO at BOOST Pharma, Lucas Arruda, CSO at CuraCell, and Brandon Cieniewicz, Director, Research & Development at CERo… Read More

#News

#Cell and gene therapy #Drug development #Drug discovery #Webinar

Webinar – Advances in cell and gene therapy

Hosted by Drug Discovery World and supported by Bio-Techne this webinar will explore the advances and challenges taking place within the cell and gene therapy field. You will hear from Hans Schambye CEO at BOOST Pharma, Lucas Arruda, CSO at CuraCell, and Brandon Cieniewicz, Director, Research & Development at CERo… Read More

#News

DDW CGT Guide
#Cell and gene therapy #Cell therapy #Gene therapy #Guide

Guide: The latest breakthroughs in cell & gene therapies

Despite their challenging nature, cell & gene therapies (CGTs) are becoming ever more successful and accessible one-time treatments for haematological malignancies and genetic diseases, while researchers have recently made significant strides forward in their use to treat other cancers.

#DDW eBooks #DDW Guides

Cell and gene therapy
#Cell and gene therapy #Cell therapy #Drug development #Drug discovery #Gene therapy

Advances and challenges in cell and gene therapies

Hosted by Drug Discovery World and supported by Bio-Techne, this webinar explores the advances and challenges taking place within the cell and gene therapy field. Hear from Hans Schambye CEO at BOOST Pharma, Lucas Arruda, CSO at CuraCell, and Brandon Cieniewicz, Director, Research & Development at CERo Therapeutics. Throughout the… Read More

Webinar date:
Sponsored by Bio-Techne
#Featured Webinars

Cell and gene therapy concept
#Advanced Therapies #Cell and gene therapy #Drug discovery #Webinar

Register now: Cell and gene therapy webinar

Hosted by Drug Discovery World and supported by Bio-Techne this webinar will explore the advances and challenges taking place within the cell and gene therapy field. You will hear from Hans Schambye CEO at BOOST Pharma, Lucas Arruda, CSO at CuraCell, and Brandon Cieniewicz, Director, Research & Development at CERo… Read More

#News

Cell and gene therapies
#Cell and gene therapy #Macrophages #Solid tumours #T-Cells

Laverock reports positive data from oncology programmes 

Laverock Therapeutics has reported in vivo functional milestones across its T-cell and macrophage oncology programmes as it advances its lead programme towards clinic.  Data from ovarian cancer models, presented at the American Society of Cell and Gene Therapy (ASCGT) Annual Meeting in May, demonstrated the company’s… Read More

#Cancer Research #News

Cell and gene therapy concept
#Cell and gene therapy #Eli Lilly #FDA #Novo Nordisk #Takeda #Tregs

A bright future for advanced therapies 

2025 was a difficult year for cell and gene therapies (CGTs), as multiple companies discontinued their cell therapy efforts, including Galapagos, Novo Nordisk and Takeda, despite significant financial losses as a result. The complexity and expense of manufacturing the treatments has meant that even when they are approved, the therapies do not always reach the relevant patients. This, alongside… Read More

#Exclusive Content

#Biotech #Cell and gene therapy #Cell and Gene Therapy Catapult #UK

How strong is the UK’s advanced therapy sector?  

DDW Editor Reece Armstrong speaks to Jacqueline Barry, Chief Clinical Officer at Cell and Gene Therapy Catapult, about the UK’s strong position in advanced therapies and what the challenges are for making the country competitive within pharma.   RA: Why does the UK have a strong in position in clinical research for advanced therapies? … Read More

#Exclusive Content

#ASGCT #Cell and gene therapy #Clinical trial #Haematology

Therapy for X-CGD shows early promise, Ensoma reports 

An in vivo therapy being developed to treat X-linked chronic granulomatous disease (X-CGD) has shown positive early results.  EN-374, developed by cellular engineering company Ensoma, has demonstrated tolerability in the first participant being evaluated in the Phase I/II trial.  The therapy is a first-in-class in vivo haematopoietic stem cell… Read More

#News

Cell and gene therapies
#ASGCT #Biotech #Cell and gene therapy

Coave to unveil capsid technology at ASGCT 2026 

Biotechnology company Coave Therapeutics is set to unveil its OneAAV universal capsid at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting.  The company will deliver two oral presentations and present two posters at the event, being held 11 – 15 May in Boston, US, showing data… Read More

#News

Cell and gene therapy concept
#Advanced Therapies #Cell and gene therapy #Cell therapy #Drug discovery #eBook #Gene therapy

eBook: Where next for cell & gene therapy?

Cell and gene therapies (CGT) have been transformative for the treatment several diseases, particularly haematological cancers and genetic conditions like sickle cell disease, with many new indications in the pipeline. This eBook, sponsored by Oxford Nanopore Technologies, explores the latest developments in advanced therapies, which treatments are securing industry investment,… Read More

#News

DDW CGT eBook
#Advanced Therapies #Cell and gene therapy #Cell therapy #Drug discovery #eBook #Gene therapy

Where next for cell & gene therapy?

This eBook, sponsored by Oxford Nanopore Technologies, explores the latest developments in advanced therapies, which treatments are securing industry investment, and the challenges and opportunities of a changing regulatory landscape.

#DDW eBooks #Intelligence

Tower Bridge, London
#Advanced Therapies #Advanced Therapy Medicinal Products (ATMPs) #Cell and gene therapy #Events

Advanced Therapies London 2026: Moving from ambition to application

Advanced Therapies 2026 took place 17 -18 March 2026 in London, UK. DDW asked industry experts for their key takeaways from the event.  Michael Baker, Director, Advanced Therapies, FUJIFILM Biotechnologies  Walking away from Advanced Therapies Week UK 2026, the focus is no longer just on what’s possible, but on what’s… Read More

#Exclusive Content

#Cell and gene therapy #Clinical trial #CRO

De-risking cell & gene therapy development with advanced analytical testing

Amy Glekas, Head of Field Development and Interim Head of Sales at Solvias, explores the opportunities that analytical testing can offer cell and gene therapy developers.  Cell and gene therapies (CGTs) have commanded public attention for decades. There are the big milestones, for example, the major gene therapy approvals, a decade of CAR T-induced cancer remission and the first patient-specific, in vivo gene editing treatment. However, in a more guarded investment climate, obstacles like adverse events and… Read More

#Exclusive Content